B-cell lymphoma treatment study with B019 injection
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests an investigational treatment called B019 for people with relapsed or refractory B-cell non-Hodgkin's lymphoma. It aims to see if this treatment can help when other treatments haven't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have B-cell non-Hodgkin's lymphoma that has come back or not responded to treatment.
- Your lymphoma cells test positive for CD19 or CD22 markers.
- You are expected to live at least 12 weeks.
- You are able to perform daily activities with some help (ECOG score 0-2).
- You have at least one measurable tumor that can be assessed.
- You are healthy enough for blood cell collection and chemotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called B019 for people whose B-cell acute lymphoblastic leukemia has come back or not responded to standard therapy. The treatment targets specific proteins on the cancer cells to help your immune system fight the leukemia.
This study is testing a new cellular therapy using immune cells (called CD20/CD19 cells) for patients with a certain type of lymphoma that has not been cured by standard treatments. The cells are designed to find and destroy your lymphoma cells, potentially helping you achieve remission.
This trial tests a new treatment for people with B-cell non-Hodgkin lymphoma that has come back after at least two prior treatments. It may help if you've already had rituximab or a similar antibody therapy.
This trial tests a new treatment called CT1190B for people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to at least two prior therapies. It aims to see if CT1190B can help when other treatments have failed or caused side effects.
This trial tests an experimental drug called CT1190B for people with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has come back or stopped responding to at least two prior treatments. The study aims to see if the drug can help control the disease.
This study tests a new cancer treatment called CT1190B for people with certain types of B-cell lymphoma that have not responded to or came back after other treatments. The goal is to see if it can help shrink or control the lymphoma.
Hear when a new Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.